Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
ApexOnco Front Page
Recent articles
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
PD-(L)1 x VEGF bispecifics prove a big draw.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Some big deals in the second quarter have raised hopes that takeouts are back.
